Profile
Wei Cao is the founder of Gracell Biotechnologies (Shanghai) Co., Ltd., founded in 2017, serving as General Manager & Executive Director.
Dr. Cao was the founder of Gracell Biotechnologies, Inc., founded in 2017, and served as Chairman & Chief Executive Officer from 2017 to 2024.
Dr. Cao is currently Chief Executive Officer at Gracell Biotechnologies (HK) Ltd., Gracell Biopharmaceuticals, Inc., and Suzhou Gracell Biotechnologies Co., Ltd. Dr. Cao is also an Independent Non-Executive Director at Zephyrm Bioscience Ltd. since 2024.
Former positions include Director at AbelZeta Pharma, Inc. in 2016 and President, Chief Operating Officer & Director at Cellular Biomedicine Group Ltd. from 2010 to 2013.
Education includes a doctorate from Medical College of Virginia, a doctorate from Harvard Medical School, and an undergraduate degree from Zhongshan Hospital Fudan University.
Wei Cao active positions
| Companies | Position | Start |
|---|---|---|
Gracell Biotechnologies (Shanghai) Co., Ltd.
Gracell Biotechnologies (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology Operates a clinical-stage biopharmaceutical company which discovers and develops cellular therapeutics for the patients suffering with cancer | Founder | 21/05/2017 |
Gracell Biotechnologies (HK) Ltd. | Chief Executive Officer | - |
Gracell Biopharmaceuticals, Inc.
Gracell Biopharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Part of AstraZeneca PLC, Gracell Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in cell therapies for cancer and autoimmune diseases. The company is based in Dover, DE. The company develops next-generation CAR-T therapies that address challenges of conventional treatments, such as long manufacturing times, immune rejection, and limited efficacy against solid tumors. Its proprietary technology platforms include FasTCAR™, which enables rapid, next-day manufacturing of autologous CAR-T cells; TruUCAR™, an off-the-shelf allogeneic CAR-T platform using gene editing to reduce graft-versus-host disease and immune rejection; and SMART CART™, designed to overcome barriers in solid tumor treatment. Gracell advances a pipeline of dual-targeted CAR-T candidates, such as GC012F targeting BCMA and CD19, currently in clinical trials for multiple myeloma and refractory systemic lupus erythematosus. The company’s manufacturing capabilities include fully closed systems and collaborations to ensure high-quality, scalable production. The CEO of the company is Wei Cao. | Chief Executive Officer | - |
Suzhou Gracell Biotechnologies Co., Ltd.
Suzhou Gracell Biotechnologies Co., Ltd. Pharmaceuticals: MajorHealth Technology Manufactures cancer cellular medicines | Chief Executive Officer | - |
Former positions of Wei Cao
| Companies | Position | End |
|---|---|---|
| GRACELL BIOTECHNOLOGIES INC. | Chief Executive Officer | 01/03/2024 |
| CELLULAR BIOMEDICINE GROUP, INC. | Chief Executive Officer | 06/02/2016 |
Cellular Biomedicine Group Ltd. | President | 01/02/2013 |
Training of Wei Cao
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 10 |
|---|---|
Medical College of Virginia
Medical College of Virginia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Medical School
Harvard Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Zhongshan Hospital Fudan University
Zhongshan Hospital Fudan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AbelZeta Pharma, Inc.
AbelZeta Pharma, Inc. BiotechnologyHealth Technology Develops cell therapies to cure cancer and inflammatory & immunological diseases | Health Technology |
Cellular Biomedicine Group Ltd. | |
Gracell Biotechnologies (Shanghai) Co., Ltd.
Gracell Biotechnologies (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology Operates a clinical-stage biopharmaceutical company which discovers and develops cellular therapeutics for the patients suffering with cancer | Health Technology |
Gracell Biotechnologies, Inc.
Gracell Biotechnologies, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops cell and gene therapy for the treatment of cancer and autoimmune diseases | Health Technology |
Gracell Biotechnologies (HK) Ltd. | |
Gracell Biopharmaceuticals, Inc.
Gracell Biopharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Part of AstraZeneca PLC, Gracell Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in cell therapies for cancer and autoimmune diseases. The company is based in Dover, DE. The company develops next-generation CAR-T therapies that address challenges of conventional treatments, such as long manufacturing times, immune rejection, and limited efficacy against solid tumors. Its proprietary technology platforms include FasTCAR™, which enables rapid, next-day manufacturing of autologous CAR-T cells; TruUCAR™, an off-the-shelf allogeneic CAR-T platform using gene editing to reduce graft-versus-host disease and immune rejection; and SMART CART™, designed to overcome barriers in solid tumor treatment. Gracell advances a pipeline of dual-targeted CAR-T candidates, such as GC012F targeting BCMA and CD19, currently in clinical trials for multiple myeloma and refractory systemic lupus erythematosus. The company’s manufacturing capabilities include fully closed systems and collaborations to ensure high-quality, scalable production. The CEO of the company is Wei Cao. | Health Services |
Suzhou Gracell Biotechnologies Co., Ltd.
Suzhou Gracell Biotechnologies Co., Ltd. Pharmaceuticals: MajorHealth Technology Manufactures cancer cellular medicines | Health Technology |
- Stock Market
- Insiders
- Wei Cao
















